PHA-665752

For research use only.

Catalog No.S1070

73 publications

PHA-665752 Chemical Structure

CAS No. 477575-56-7

PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.

Selleck's PHA-665752 has been cited by 73 publications

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.
Targets
c-Met [1]
(Cell-free assay)
RON [1]
(Cell-free assay)
Flk1 [1]
(Cell-free assay)
9 nM 68 nM 200 nM
In vitro

PHA-665752 significantly inhibits c-Met kinase activity with Ki of 4 nM, and exhibits >50-fold selectivity for c-Met compared with various tyrosine and serine-threonine kinases. PHA-665752 potently inhibits the HGF-stimulated c-Met autophosphorylation with IC50 of 25-50 nM. PHA-665752 also significantly blocks HGF- and c-Met-dependent functions such as cell motility and cell proliferation with IC50 of 40-50 nM and 18-42 nM, respectively. In addition, PHA-665752 potently inhibits HGF-stimulated or constitutive phosphorylation of mediators of downstream of c-Met such as Gab-1, ERK, Akt, STAT3, PLC-γ, and FAK in multiple tumor cell lines. [1] PHA-665752 inhibits cell growth in TPR-MET-transformed BaF3 cells with IC50 of <60 nM, and inhibits constitutive cell motility and migration by 92.5% at 0.2 μM. Inhibition of c-Met by PHA665752 (0.2 μM) also induces cell apoptosis of 33.1% and G1 cell cycle arrest with cells in G1 phase increasing from 42.4% to 77.0%. PHA665752 can cooperate with rapamycin to inhibit cell growth of TPR-MET-transformed BaF3 cells and non-small cell lung cancer H441 cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-SNU-5 NH7IXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMUKzO|Uh|ryP NYTXOpVuW0GQR1XS
LB2241-RCC MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMUW3NFIh|ryP NVrkcXAzW0GQR1XS
KINGS-1 NWHQfnJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\xUmlEPTB;MD6zOVkyOSEQvF2= MVnTRW5ITVJ?
ALL-PO NEi3dFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwOEGyO|ch|ryP NHrJb5pUSU6JRWK=
SK-LMS-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwOEm4OFYh|ryP MY\TRW5ITVJ?
MV-4-11 M1XxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGiweolKSzVyPUGuNlk1PyEQvF2= NID4d2JUSU6JRWK=
SUP-T1 M2nIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PBPGlEPTB;Mj6xN|k3PCEQvF2= NW\ETZRjW0GQR1XS
MRK-nu-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrzflhGUUN3ME2yMlQxODV4IN88US=> MXfTRW5ITVJ?
ES1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDnXmdWUUN3ME2zMlM1QDZ4IN88US=> NX\yXldKW0GQR1XS
NOS-1 MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP3TWM2OD12LkO5PFY4KM7:TR?= M3HIXHNCVkeHUh?=
KM12 M1zvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRwNEG4JO69VQ>? MX3TRW5ITVJ?
Becker NFSxVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzzeZNKSzVyPUWuNlQ3PiEQvF2= NYTmW3lLW0GQR1XS
NCI-SNU-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTVwNkO3N|Mh|ryP NWmxNZdwW0GQR1XS
EW-22 M4PK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzGTWM2OD15LkezOlE1KM7:TR?= MWPTRW5ITVJ?
ES6 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\STWM2OD15LkixPVUh|ryP MUXTRW5ITVJ?
A498 NXPlbHM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnJRoR2UUN3ME24MlI5PDR4IN88US=> NUDvN2NSW0GQR1XS
EW-16 M4naN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS1RVJUUUN3ME25MlY2PDNizszN NI\NRY1USU6JRWK=
CTV-1 NHfh[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PMW2lEPTB;OT64OVAzPCEQvF2= NGroeXBUSU6JRWK=
ETK-1 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LwTGlEPTB;MUCuNlk{OSEQvF2= NH;mV4lUSU6JRWK=
NCI-H1395 NFO5[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17YTWlEPTB;MUCuPFAzPCEQvF2= M3Poe3NCVkeHUh?=
DOHH-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPXO5gyUUN3ME2xNE46OjZ2IN88US=> MonGV2FPT0WU
GI-1 NVjoW5NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O1NmlEPTB;MUGuPFU6PiEQvF2= NVuwclNNW0GQR1XS
HT-144 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nDcWlEPTB;MUSuNlE3OyEQvF2= NEPn[|lUSU6JRWK=
ES5 NFn2XJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Hke2lEPTB;MUSuOFY4KM7:TR?= M1;YUXNCVkeHUh?=
NALM-6 NVy3emdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHNeIVGUUN3ME2xOU4zOTl4IN88US=> MXfTRW5ITVJ?
KNS-81-FD NVrxbZNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TPVmlEPTB;MUWuOVg1QSEQvF2= M1TWdHNCVkeHUh?=
TE-15 NWLJc2dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX65doJNUUN3ME2xOk42PzdzIN88US=> MUPTRW5ITVJ?
SCC-15 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XVdWlEPTB;MUiuN|Q6QCEQvF2= NWrNZ5plW0GQR1XS
EoL-1-cell NFexOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;2TWM2OD1zOD60OVQ2KM7:TR?= NEX3ZppUSU6JRWK=
NCI-H720 NY\5TGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojNTWM2OD1zOD63O|Eh|ryP NELEWpNUSU6JRWK=
NB14 NILzfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HseWlEPTB;MUmuOVQzPSEQvF2= MWrTRW5ITVJ?
KE-37 MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrabVZOUUN3ME2xPU45OjN|IN88US=> M3rBVXNCVkeHUh?=
LXF-289 NH;ZNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfhZlhKSzVyPUG5Mlg3OjlizszN NVHibVVQW0GQR1XS
RPMI-8402 M360TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHQ[5pnUUN3ME2yNE4{OjZ7IN88US=> MXnTRW5ITVJ?
SK-N-DZ NHPRRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJzLkKxN|Eh|ryP M1O4OXNCVkeHUh?=
ACN Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDDZZpKSzVyPUKyMlI1QTdizszN NI\BR29USU6JRWK=
TE-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInnTlFKSzVyPUK2MlA3QSEQvF2= M1TKPHNCVkeHUh?=
COLO-800 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ5LkG3JO69VQ>? MX\TRW5ITVJ?
MOLT-13 NWi3c2lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K5[GlEPTB;MkeuNVg1PyEQvF2= MVjTRW5ITVJ?
697 NYrmbGJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\sTWM2OD1{OD63OlM{KM7:TR?= MY\TRW5ITVJ?
VA-ES-BJ MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\sTWM2OD1{OT6zO|I6KM7:TR?= MU\TRW5ITVJ?
EW-13 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTvTWM2OD1{OT61NFQ2KM7:TR?= MWHTRW5ITVJ?
NB7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPIXlhKSzVyPUOyMlI3PjVizszN NWTPRXZIW0GQR1XS
MONO-MAC-6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HWSWlEPTB;M{KuPFc6PSEQvF2= M1\mTHNCVkeHUh?=
SW962 NFXZWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTN|LkS1NVMh|ryP MXTTRW5ITVJ?
KS-1 NFG1Um5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly3TWM2OD1|Mz65OFgyKM7:TR?= NEDBZ4pUSU6JRWK=
KU812 M1vzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHIR4NKSzVyPUO0MlU4ODJizszN M{TiTHNCVkeHUh?=
IMR-5 NVHzc2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVywN5U6UUN3ME2zO{41OzF6IN88US=> NUf3eG9vW0GQR1XS
BC-1 NViw[ZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfmOVVsUUN3ME2zPE4xOzNizszN NYDEPZVHW0GQR1XS
NCI-H510A NFruTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETTdHFKSzVyPUO4MlIxOzJizszN NUH1dZNSW0GQR1XS
EW-18 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml35TWM2OD12MD64N|A{KM7:TR?= NFHNOnVUSU6JRWK=
CCRF-CEM MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fiXGlEPTB;NEKuNlc6PyEQvF2= NY[5N45xW0GQR1XS
HH NY\iV5VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\0TWM2OD12Mz61NFY6KM7:TR?= Moe2V2FPT0WU
NCI-H2171 NGHIVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTtZZFmUUN3ME20Ok4xOjd{IN88US=> MV\TRW5ITVJ?
LC-2-ad M{HVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTR7LkG0NVMh|ryP MnHyV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Met / Met / p-Akt / Akt / p-ERK / ERK ; 

PubMed: 25226813     


HCC827 GR6 cells were treated for 6 h with increasing concentrations of tivantinib or PHA-665752. Cell lysates were immunoblotted to detect indicated proteins. PHA-665752 partially inhibits MET and ERK1/2 phosphorylation but not AKT. Tivantinib did not inhibit MET phosphorylation or downstream signaling.

IDO; 

PubMed: 27082119     


PHA-665752 inhibited both c-Met phosphorylation and IDO expression of SKOV-3 cells in a concentration-dependent manner.

25226813 27082119
Growth inhibition assay
Cell proliferation ; 

PubMed: 20603611     


Cell proliferation was evaluated at fixed times after the addition of HGF (50 ng/ml) +/− PHA-665752 (d) at different concentrations in 2% FBS-containing medium. PHA-665752 showed a marked reduction in cell numbers starting from 24 h at micromolar concentrations (5 and 10 μ), whereas lower concentrations did not exert a significant reduction of proliferation with respect to the control. 

20603611
In vivo Administration of PHA-665752 induces a dose-dependent tumor growth inhibition of S114 xenografts by 20 %, 39% and 68%, at dose of 7.5, 15, and 30 mg/kg/day, respectively. [1] PHA665752 treatment significantly reduces the tumor growth of NCI-H69, NCI-H441 and A549 in mouse xenografts by 99%, 75%, and 59%, respectively. PHA665752 also significantly inhibits angiogenesis by >85%, due to decreasing the production of vascular endothelial growth factor and increasing the production of the angiogenesis inhibitor thrombospondin-1. [3]

Protocol

Kinase Assay:[1]
- Collapse

In vitro enzyme assay:

The c-Met kinase domain GST-fusion protein is used for the c-Met assay. The IC50 value of PHA-665752 for the inhibition of c-Met is based on phosphorylation of kinase peptide substrates or poly-glu-tyr in the presence of ATP and divalent cation (MgCl2 or MnCl2 10-20 mM). The linear range (i.e., the time period over which the rate remains equivalent to the initial rate) is determined for c-Met, and the kinetic measurement and IC50 determination are performed within this range.
Cell Research:[1]
- Collapse
  • Cell lines: S114, GTL-16, NCI-H441, and BxPC-3
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 18, or 72 hours
  • Method: For proliferation assays, cells are grown in medium with 0.1% FBS for 48 hours after which they are treated with various concentrations of PHA-665752 in HGF (50 ng/mL) in a medium containing 2% FBS. After 18 hours, cells are incubated with BrdUrd for 1 hour, fixed, and stained with anti-BrdUrd peroxidase-conjugated antibody, and plates are read at 630 nm. For apoptosis assays, cells are grown in medium with 2% FBS in presence and absence of HGF (50 ng/mL) and various concentrations of PHA-665752 for 72 hours. After 72 hours, a mixture containing ethidium bromide and acridine orange is added, and apoptotic cells (bright orange cells or cell fragments) are counted by fluorescence microscopy.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female athymic mice (nu/nu) bearing S114 or GTL-16 tumor xenografts
  • Dosages: ~30 mg/kg/day
  • Administration: Injection via bolus i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 128 mg/mL (199.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+castor oil
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 641.61
Formula

C32H34Cl2N4O4S

CAS No. 477575-56-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=C(NC(=C1C(=O)N2CCCC2CN3CCCC3)C)C=C4C5=C(C=CC(=C5)S(=O)(=O)CC6=C(C=CC=C6Cl)Cl)NC4=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I need to use S1070 for intraperitoneal application in mice. Could you tell me the solvent you use, please?

  • Answer:

    The highest concentration of PHA-665752 (S1070) in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O is 5mg/ml. If you want to get higher concentration, the concentration of DMSO and PEG will be higher. For example, it can be dissolved in 8% DMSO+50% PEG 300+5% Tween 80+ddH2O at 10mg/ml clearly.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy PHA-665752 | PHA-665752 supplier | purchase PHA-665752 | PHA-665752 cost | PHA-665752 manufacturer | order PHA-665752 | PHA-665752 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID